Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Alzheimers Dis. 2010;21(3):903-14. doi: 10.3233/JAD-2010-100408.

A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Author information

  • 1Portland Veterans Affairs Medical Center, P3 R&D, Portland, OR, USA. quinnj@ohsu.edu

Abstract

There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.

PMID:
20693639
[PubMed - indexed for MEDLINE]
PMCID:
PMC2940947
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for IOS Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk